Senseonics (NYSE:SENS) Announces Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Senseonics (NYSE:SENS - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.09), RTT News reports. Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same quarter in the previous year, the business earned ($0.07) EPS. Senseonics updated its FY 2025 guidance to EPS.

Senseonics Price Performance

Senseonics stock traded up $0.03 during trading on Friday, reaching $0.65. The company had a trading volume of 11,502,141 shares, compared to its average volume of 14,658,552. The firm's 50-day simple moving average is $0.86 and its 200 day simple moving average is $0.53. Senseonics has a 1-year low of $0.25 and a 1-year high of $1.40. The firm has a market capitalization of $384.88 million, a PE ratio of -4.97 and a beta of 1.17. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Insiders Place Their Bets

In other Senseonics news, CEO Timothy T. Goodnow bought 315,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were bought at an average price of $0.31 per share, with a total value of $97,650.00. Following the purchase, the chief executive officer now directly owns 11,310,355 shares in the company, valued at $3,506,210.05. This trade represents a 2.86 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Frederick T. Sullivan bought 124,933 shares of the stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the purchase, the chief financial officer now owns 2,478,844 shares in the company, valued at $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on SENS shares. StockNews.com started coverage on shares of Senseonics in a research note on Thursday, December 26th. They issued a "sell" rating on the stock. HC Wainwright reissued a "buy" rating and issued a $2.00 price target on shares of Senseonics in a research note on Wednesday.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.